158 related articles for article (PubMed ID: 11641785)
1. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
Lafarge S; Sylvain V; Ferrara M; Bignon YJ
Oncogene; 2001 Oct; 20(45):6597-606. PubMed ID: 11641785
[TBL] [Abstract][Full Text] [Related]
2. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
3. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells.
Shtil AA; Mandlekar S; Yu R; Walter RJ; Hagen K; Tan TH; Roninson IB; Kong AN
Oncogene; 1999 Jan; 18(2):377-84. PubMed ID: 9927194
[TBL] [Abstract][Full Text] [Related]
4. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
5. c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the levels of stathmin/oncoprotein 18.
Yeap YY; Ng IH; Badrian B; Nguyen TV; Yip YY; Dhillon AS; Mutsaers SE; Silke J; Bogoyevitch MA; Ng DC
Biochem J; 2010 Sep; 430(2):345-54. PubMed ID: 20594188
[TBL] [Abstract][Full Text] [Related]
6. BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.
Nakuci E; Mahner S; Direnzo J; ElShamy WM
Exp Cell Res; 2006 Oct; 312(16):3120-31. PubMed ID: 16860316
[TBL] [Abstract][Full Text] [Related]
7. c-Jun controls the efficiency of MAP kinase signaling by transcriptional repression of MAP kinase phosphatases.
Sprowles A; Robinson D; Wu YM; Kung HJ; Wisdom R
Exp Cell Res; 2005 Aug; 308(2):459-68. PubMed ID: 15950217
[TBL] [Abstract][Full Text] [Related]
8. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork.
Hosseini M; Rose AY; Song K; Bohan C; Alexander JP; Kelley MJ; Acott TS
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1469-76. PubMed ID: 16565381
[TBL] [Abstract][Full Text] [Related]
9. [The role of MAPK pathways in hsp90 genes expression].
Li J; Wu N; Shen Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Aug; 22(4):327-31. PubMed ID: 12903443
[TBL] [Abstract][Full Text] [Related]
10. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor c-Jun activation represses mdr-1 gene expression.
Miao ZH; Ding J
Cancer Res; 2003 Aug; 63(15):4527-32. PubMed ID: 12907627
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Gancz D; Donin N; Fishelson Z
Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid inhibits hepatic Jun N-terminal kinase-dependent signaling pathway in ethanol-fed rats.
Chung J; Chavez PR; Russell RM; Wang XD
Oncogene; 2002 Feb; 21(10):1539-47. PubMed ID: 11896582
[TBL] [Abstract][Full Text] [Related]
15. [Heat shock activated Rac-MEKK-JNK pathway and hsp90 beta gene expression].
Li XY; Lu C; Wu NH; Shen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):264-8. PubMed ID: 12905631
[TBL] [Abstract][Full Text] [Related]
16. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
17. Differentiation-associated genes regulated by TPA-induced c-Jun expression via a PKC/JNK pathway in KYSE450 cells.
Yu X; Luo A; Zhou C; Ding F; Wu M; Zhan Q; Liu Z
Biochem Biophys Res Commun; 2006 Mar; 342(1):286-92. PubMed ID: 16480952
[TBL] [Abstract][Full Text] [Related]
18. Characterization of HSP27 phosphorylation induced by microtubule interfering agents: implication of p38 signalling pathway.
Casado P; Zuazua-Villar P; Prado MA; Valle ED; Iglesias JM; MartÃnez-Campa C; Lazo PS; Ramos S
Arch Biochem Biophys; 2007 May; 461(1):123-9. PubMed ID: 17367746
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes.
Singh R; Ahmed S; Malemud CJ; Goldberg VM; Haqqi TM
J Orthop Res; 2003 Jan; 21(1):102-9. PubMed ID: 12507586
[TBL] [Abstract][Full Text] [Related]
20. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
